Results 81 to 90 of about 71,439 (210)

Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]

, 2015
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján, Mathet, Veronica Lidia, Oubiña, Jose Raul   +2 more
core   +1 more source

The newfound relationship between extrachromosomal DNAs and excised signal circles

FEBS Letters, Volume 600, Issue 9, Page 1265-1287, May 2026.
Extrachromosomal DNAs (ecDNAs) contribute to the progression of many human cancers. In addition, circular DNA by‐products of V(D)J recombination, excised signal circles (ESCs), have roles in cancer progression but have largely been overlooked. In this Review, we explore the roles of ecDNAs and ESCs in cancer development, and highlight why these ...
Dylan Casey, Zeqian Gao, Joan Boyes
wiley   +1 more source

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review [PDF]

, 2018
Pancreatic cancer has a dismal prognosis particularly in patients presenting with unresectable tumors. We performed a bibliometric analysis of clinical trials for pancreatic cancer conducted between 2014-2016 focusing on patients that presented with ...
Biankin, Andrew V., Khachigian, Levon M., Parish, Christopher R., Sheahan, Anjali V.   +3 more
core   +1 more source

Deciphering and Targeting the Schwannoma‐Neuron‐Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain

Advanced Science, Volume 13, Issue 26, 8 May 2026.
We established patient‐derived SWN cell lines and orthotopic PDX models that recapitulate patient pain phenotypes, alongside a novel intravital DRG imaging platform to track macrophage infiltration and neuronal pain responses. Using these models, we define HMGB1–CCL2–IL‐6 signaling crosstalk driving pain and identify EGF signaling as a key regulator of
Zhenzhen Yin, Limeng Wu, Yanling Zhang, Yao Sun, Grace Y. Lee, Simeng Lu, Xing Gao, John W. Chen, Sonu Subudhi, William Ho, Chao Zhu, Jun Ren, Gino B. Ferraro, Alona Muzikansky, Anat Stemmer‐Rachamimov, Jianren Mao, Scott R. Plotkin, Lei Xu   +17 more
wiley   +1 more source

Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer

Di-san junyi daxue xuebao, 2020
Objective To observe the expression of hexokinase 2 (HK2), a key enzyme of glycolysis, in human non-small cell lung cancer (NSCLC) tissues, and to investigate the role and mechanism of HK2 in the resistance of NSCLC to erlotinib. Methods The relationship
YOU Qi, ZHUO Wenlei, CHEN Zhengtang
doaj   +1 more source

Liquid biopsy genotyping in lung cancer: ready for clinical utility? [PDF]

, 2017
Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its ...
Chen, Yi-Lin, Ho, Chung-Liang, Huang, Wei-Lun, Lin, Chien-Chung, Su, Wu-Chou, Wei, Fang, Wong, David T, Yang, Szu-Chun   +7 more
core   +1 more source

Stanniocalcin 2‐Induced Autophagy Confers Resistance of Lung Cancer Cells to EGFR Inhibition via the ERK/Beclin 1 Signaling

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are effective in treating NSCLC with EGFR mutations, the development of resistance limits their long‐term efficacy. Autophagy has been implicated as a potential mechanism behind this acquired resistance.
Yi‐Nan Liu, Yi‐Ling Chen, Meng‐Feng Tsai, Shang‐Gin Wu, Tzu‐Hua Chang, Tzu‐Hsiu Tsai, Jin‐Yuan Shih   +6 more
wiley   +1 more source

Programmable biomaterials for dynamic and responsive drug delivery [PDF]

, 2016
Biomaterials are continually being designed that enable new methods for interacting dynamically with cell and tissues, in turn unlocking new capabilities in areas ranging from drug delivery to regenerative medicine. In this review, we explore some of the
Almquist, BD, Kiani, MT, Stejskalova, A
core   +1 more source

Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Purpose Patients with advanced epidermal growth factor receptor (EGFR)‐mutated adenocarcinoma often receive frontline first‐ and second‐generation EGFR tyrosine kinase inhibitor (TKI) treatments in Taiwan. However, upon progression, not all patients undergo rebiopsy for molecular testing.
Min‐Hsi Lin, Kuo‐An Chu, Chiu‐Fan Chen, You‐Cheng Jiang, Wei‐Cheng Hong, Ming‐Yen Hung, Chun‐Hsiang Hsu   +6 more
wiley   +1 more source

A Drug–Drug Interaction Study to Evaluate the Impact of Simvastatin and Itraconazole on Erlotinib Pharmacokinetics in Rats by UPLC-MS/MS

Drug Design, Development and Therapy, 2023
Zaiwen Fan,1 Xiaonan Gao,2 Mingxia Wang,2 Ziqiang Tian1 1Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China; 2Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical
Fan Z, Gao X, Wang M, Tian Z
doaj